A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

• Status: Terminated
• Trial end date: 2018-10-02
• Target enrollment: 0
• Participant gender: All

Summary

This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca; Eli Lilly and Company
• Collaborators: AstraZeneca; Eli Lilly and Company

Criteria

Inclusion Criteria:

• Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility criteria for delayed-start I8D-MC-AZFD.

Exclusion Criteria:

• Participants who participate in AMARANTH (NCT02245737) who develop new conditions precluding them from enrolling into I8D-MC-AZFD.